https://orcid.org/0000-0001-9512-4118
References
- Chang AE, Karnell LH, Menck HR. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. Cancer. 1998;83(8):1664–1678.
- Troussier I, Baglin AC, Marcy PY, et al. Mucosal melanomas of the head and neck: state of the art and current controversies. Bull Cancer. 2015;102:559–567.
- Colevas AD, Yom SS, Pfister DG, et al. NCCN guidelines insights: head and neck cancers, version 1.2018. J Natl Compr Canc Netw. 2018;16(5):479–490.
- Nenclares P, Ap Dafydd D, Bagwan I, et al. Head and neck mucosal melanoma: The United Kingdom national guidelines. Eur J Cancer. 2020;138:11–18.
- Soft Tissue Tumor and Melanoma Group of Sarcoma Committee, Chinese Anti-Cancer Association. Chinese expert consensus on the surgical treatment of cutaneous/acral melanoma V1.0. Zhonghua Zhong Liu Za Zhi. 2020;42(2):81–93.
- Amit M, Tam S, Abdelmeguid AS, et al. Role of adjuvant treatment in sinonasal mucosal melanoma. J Neurol Surg B Skull Base. 2017;78(6):512–518.
- Li W, Yu Y, Wang H, et al. Evaluation of the prognostic impact of postoperative adjuvant radiotherapy on head and neck mucosal melanoma: a meta-analysis. BMC Cancer. 2015;15(1):758.
- Yin GF, Guo W, Chen Xh, et al. Clinical characteristic and prognostic analyses of 117 cases of head and neck mucosal melanoma. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2018; 753(9):668–674.
- Grant-Freemantle MC, Lane O'Neill B, Clover AJP. The effectiveness of radiotherapy in the treatment of head and neck mucosal melanoma: Systematic review and meta-analysis. Head Neck. 2021;43(1):323–333.
- Hu R, Yang BB. Surgery alone versus post-operative radiotherapy for sinonasal malignant melanoma: a meta-analysis. J Laryngol Otol. 2018;132(12):1051–1060.
- Li C, Zhang Q, Li Z, et al. Efficacy and safety of carbon-ion radiotherapy for the malignant melanoma: a systematic review. Cancer Med. 2020;9(15):5293–5305.
- Ahn HJ, Na II, Park YH, et al. Role of adjuvant chemotherapy in malignant mucosal melanoma of the head and neck. Oral Oncol. 2010;46(8):607–611.
- Lian B, Si L, Cui C, et al. Phase II randomized trial comparing high-dose IFN-alpha2b with temozolomide plus cisplatin as systemic adjuvant therapy for resected mucosal melanoma. Clin Cancer Res. 2013;19(16):4488–4498.
- Lian B, Cui C, Song X, et al. Phase III randomized, multicenter trial comparing high-dose IFN-a2b with temozolomide plus cisplatin as adjuvant therapy for resected mucosal melanoma. J Clin Oncol. 2018;36(15_suppl):9589–9589.
- D'Angelo SP, Larkin J, Sosman JA, et al. Efficacy and safety of nivolumab alone or in combination with ipilimumab in patients with mucosal melanoma: a pooled analysis. J Clin Oncol. 2017;35:226–235.
- Chalmers ZR, Connelly CF, Fabrizio D, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017;9(1):34.
- Furney SJ, Turajlic S, Stamp G, et al. Genome sequencing of mucosal melanomas reveals that they are driven by distinct mechanisms from cutaneous melanoma. J Pathol. 2013;230(3):261–269.
- Moya-Plana A, Herrera Gómez RG, Rossoni C, et al. Evaluation of the efficacy of immunotherapy for non-resectable mucosal melanoma. Cancer Immunol Immunother. 2019;68(7):1171–1178.
- Teterycz P, Czarnecka AM, Indini A, et al. Multimodal treatment of advanced mucosal melanoma in the era of modern immunotherapy. Cancers (Basel. 2020;12(11):3131.